DK0823897T3
(da)
*
|
1995-05-01 |
2004-12-06 |
Scarista Ltd |
Nicotinsyreestere og farmaceutiske præparater indeholdende disse
|
MY118354A
(en)
*
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
USRE40546E1
(en)
*
|
1996-05-01 |
2008-10-21 |
Scarista, Ltd. |
1,3-Propane diol esters and ethers and methods for their use in drug delivery
|
US5795909A
(en)
*
|
1996-05-22 |
1998-08-18 |
Neuromedica, Inc. |
DHA-pharmaceutical agent conjugates of taxanes
|
US6576636B2
(en)
*
|
1996-05-22 |
2003-06-10 |
Protarga, Inc. |
Method of treating a liver disorder with fatty acid-antiviral agent conjugates
|
WO1997048391A2
(en)
*
|
1996-06-21 |
1997-12-24 |
Advanced Research And Technology Institute |
Methods and compositions comprising r-ibuprofen
|
BR9713346A
(pt)
*
|
1996-11-12 |
2000-05-09 |
American Home Prod |
Inibidores de indenos de cox - 2
|
US5869524A
(en)
*
|
1996-11-12 |
1999-02-09 |
American Home Products Corporation |
Indene inhibitors of COX-2
|
WO1998027972A2
(en)
*
|
1996-12-23 |
1998-07-02 |
Texas A & M University |
Anti-amyloidogenic agents
|
AU6959898A
(en)
|
1997-04-11 |
1998-11-11 |
David J. Grainger |
Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
|
WO1999040926A1
(en)
*
|
1998-02-13 |
1999-08-19 |
Nutramax Laboratories, Inc. |
Agents and methods for protection, treatment and repair of connective tissue
|
US6149964A
(en)
*
|
1998-05-21 |
2000-11-21 |
Beech-Nut Nutrition Corporation |
Egg yolk-containing baby food compositions and methods therefor
|
US7413759B2
(en)
*
|
1998-05-21 |
2008-08-19 |
Beech-Nut Nutrition Corporation |
Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
|
US7141266B2
(en)
*
|
1998-05-21 |
2006-11-28 |
Beech-Nut Nutrition Corporation |
Baby-food compositions enhancing visual acuity and methods therefor
|
US6579551B1
(en)
|
1998-05-21 |
2003-06-17 |
Beech-Nut Nutrition Corporation |
Baby-food compositions containing egg yolk and methods therefor
|
US6572871B1
(en)
*
|
1999-01-06 |
2003-06-03 |
W. Edward Church |
Pain treatment method and apparatus using heating wrap and analgesic cream
|
US20040073258A1
(en)
*
|
1999-01-06 |
2004-04-15 |
Church W. Edward |
Body tissue and skin treatment method using pulsing heating pad and topical cream
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
US7235583B1
(en)
*
|
1999-03-09 |
2007-06-26 |
Luitpold Pharmaceuticals, Inc., |
Fatty acid-anticancer conjugates and uses thereof
|
US6426367B1
(en)
*
|
1999-09-09 |
2002-07-30 |
Efa Sciences Llc |
Methods for selectively occluding blood supplies to neoplasias
|
US20060004086A1
(en)
*
|
2000-04-13 |
2006-01-05 |
Mayo Foundation For Medical Education And Research |
Method of reducing Abeta42 and treating diseases
|
AU5702201A
(en)
*
|
2000-04-13 |
2001-10-30 |
Mayo Foundation |
Abeta<sub>42</sub> lowering agents
|
WO2001093680A1
(en)
*
|
2000-06-02 |
2001-12-13 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
US6306842B1
(en)
*
|
2000-06-02 |
2001-10-23 |
Medinox, Inc. |
Protected forms of a combination of pharmacologically active agents and uses therefor
|
WO2002009725A1
(en)
*
|
2000-08-02 |
2002-02-07 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflamation, osteoarthritis, and other degenerative joint diseases
|
US6838451B1
(en)
|
2000-08-02 |
2005-01-04 |
Pharmanutrients |
Methods and compositions for the prevention and treatment of inflammation, osteoarthritis, and other degenerative joint diseases
|
US6927239B1
(en)
*
|
2000-08-02 |
2005-08-09 |
Pharmanutrients |
Methods and compositions for the attenuation and/or prevention of stress/catabolic responses
|
EP1305017A4
(en)
|
2000-08-02 |
2004-01-14 |
Pharmanutrients |
METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SYNDROME X
|
JP2004538262A
(ja)
*
|
2000-12-14 |
2004-12-24 |
タフツ ユニバーシティー |
関節炎状態を治療するための化合物および方法
|
WO2002076402A2
(en)
*
|
2001-03-23 |
2002-10-03 |
Protarga, Inc. |
Fatty amine drug conjugates
|
JP4634694B2
(ja)
*
|
2001-03-23 |
2011-02-16 |
ルイトポルド・ファーマシューティカルズ・インコーポレーテッド |
脂肪アルコール薬物複合体
|
GB0111282D0
(en)
*
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
JP3977162B2
(ja)
*
|
2002-06-21 |
2007-09-19 |
株式会社バンダイナムコゲームス |
キャラクタ情報管理装置、プログラム及び情報記憶媒体
|
WO2004071431A2
(en)
*
|
2003-02-05 |
2004-08-26 |
Myriad Genetics, Inc. |
Method and composition for treating neurodegenerative disorders
|
AU2004311577A1
(en)
*
|
2003-07-11 |
2005-07-21 |
Myriad Genetics, Inc. |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
US20050154059A1
(en)
*
|
2004-01-13 |
2005-07-14 |
Cook Mark E. |
Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid
|
WO2005092062A2
(en)
*
|
2004-03-19 |
2005-10-06 |
Myriad Genetics, Inc. |
Compounds for neurodegenerative disorders
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
US20050252144A1
(en)
*
|
2004-04-29 |
2005-11-17 |
Macdonald Robert A |
Veneers for walls, retaining walls and the like
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
BRPI0514303A
(pt)
*
|
2004-08-11 |
2008-06-10 |
Myriad Genetics Inc |
composição farmacêutica e método para tratar distúrbios neurodegenerativos
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US7893106B2
(en)
*
|
2004-11-19 |
2011-02-22 |
Martek Biosciences, Corporation |
Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
|
CA2588166A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Martek Biosciences Corporation |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
US20090318394A1
(en)
*
|
2004-11-19 |
2009-12-24 |
Julie Nauroth |
Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
|
CA2615063A1
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
WO2007090162A2
(en)
*
|
2006-01-31 |
2007-08-09 |
Martek Biosciences Corporation |
OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
|
US20080033045A1
(en)
*
|
2006-07-07 |
2008-02-07 |
Myriad Genetics, Incorporated |
Treatment of psychiatric disorders
|
JP2010519311A
(ja)
*
|
2007-02-20 |
2010-06-03 |
マーテック バイオサイエンシーズ コーポレーション |
長鎖多価不飽和脂肪酸由来のオキシリピンならびにその作製およびその使用方法
|
WO2008153722A1
(en)
*
|
2007-05-22 |
2008-12-18 |
The Board Of Regents Of The University Of Texas System |
Post-translational regulation of catalytic activities of cytochrome p450 46a1 and uses thereof
|
WO2009086281A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Martek Biosciences Corporation |
Method for preparation of oxylipins
|
ES2656903T3
(es)
|
2008-07-08 |
2018-02-28 |
Catabasis Pharmaceuticals, Inc. |
Salicilatos acetilados de ácidos grasos y sus usos
|
US9085527B2
(en)
*
|
2008-07-08 |
2015-07-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid acylated salicylates and their uses
|
EP3578177A1
(en)
|
2008-09-02 |
2019-12-11 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
|
US20110229565A1
(en)
*
|
2008-09-17 |
2011-09-22 |
Karp Jeffrey M |
Drug Delivery Composition Comprising a Self-Assembled Gelator
|
CA2739352C
(en)
|
2008-10-29 |
2021-07-13 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
CA2738243C
(en)
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
EP2596786B1
(en)
|
2009-02-10 |
2019-11-27 |
Amarin Pharmaceuticals Ireland Limited |
Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
|
RU2538691C2
(ru)
|
2009-04-29 |
2015-01-10 |
Амарин Фарма, Инк. |
Стабильные фармацевтические композиции и способы их применения
|
EP3563842A1
(en)
|
2009-04-29 |
2019-11-06 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
LT3318255T
(lt)
|
2009-06-15 |
2021-05-25 |
Amarin Pharmaceuticals Ireland Limited |
Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija
|
MY158504A
(en)
|
2009-09-01 |
2016-10-14 |
Catabasis Pharmaceuticals Inc |
Fatty acid niacin conjugates and their uses
|
USRE46608E1
(en)
|
2009-09-01 |
2017-11-14 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid niacin conjugates and their uses
|
US20110064813A1
(en)
*
|
2009-09-16 |
2011-03-17 |
Charles Vaughn |
Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet
|
CA2775339C
(en)
|
2009-09-23 |
2017-03-28 |
Amarin Corporation Plc |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
CA2889457C
(en)
|
2009-12-31 |
2016-06-28 |
Kempharm, Inc. |
Amino acid conjugates of quetiapine, process for making and using the same
|
AR079957A1
(es)
*
|
2010-01-20 |
2012-02-29 |
Pronova Biopharma Norge As |
Derivados de acidos grasos de salicilatos composiciones farmaceuticas y uso de los mismos
|
EP3583849A1
(en)
*
|
2010-03-04 |
2019-12-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US9216224B2
(en)
|
2010-03-05 |
2015-12-22 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid COX inhibitor derivatives and their uses
|
HUE042945T2
(hu)
|
2010-03-11 |
2019-07-29 |
Kempharm Inc |
Kvetiapin zsírsav-konjugátumai, eljárás ugyanannak elkészítésére és felhasználására
|
US20130045939A1
(en)
*
|
2010-03-19 |
2013-02-21 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid macrolide derivatives and their uses
|
EP2593476A2
(en)
*
|
2010-07-16 |
2013-05-22 |
Ablynx N.V. |
Modified single domain antigen binding molecules and uses thereof
|
EP4079292A1
(en)
|
2010-09-24 |
2022-10-26 |
The Brigham and Women's Hospital, Inc. |
Nanostructured gels capable of controlled release of encapsulated agents
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
NZ744990A
(en)
|
2010-11-29 |
2019-10-25 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
CA2822263A1
(en)
*
|
2010-12-21 |
2012-06-28 |
Nestec S.A. |
Methods and compositions for preventing and treating osteoarthritis
|
CA2850187C
(en)
*
|
2011-09-29 |
2021-12-07 |
Plx Pharma Inc. |
Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
EP2775837A4
(en)
|
2011-11-07 |
2015-10-28 |
Amarin Pharmaceuticals Ie Ltd |
METHODS OF TREATING HYPERTRIGLYCERIDEMIA
|
EP2800469B1
(en)
|
2012-01-06 |
2021-08-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
EP4342546A3
(en)
|
2012-06-29 |
2024-05-22 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
|
US20150265566A1
(en)
|
2012-11-06 |
2015-09-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
TW202348234A
(zh)
|
2013-12-24 |
2023-12-16 |
維吉尼亞聯邦大學 |
氧化膽固醇硫酸鹽(ocs)之用途
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
WO2016191323A1
(en)
|
2015-05-22 |
2016-12-01 |
University Of South Florida |
Lithium co-crystals for treatment of neuropsychiatric disorders
|
CN108289833B
(zh)
|
2015-10-08 |
2022-01-25 |
布里格姆及妇女医院股份有限公司 |
用于递送囊封剂的稳定的已组装纳米结构
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US10568840B2
(en)
|
2016-05-06 |
2020-02-25 |
The Brigham And Women's Hospital, Inc. |
Self assembled gels for controlled delivery of encapsulated agents to cartilage
|
US11020410B2
(en)
|
2017-02-03 |
2021-06-01 |
The Brigham And Women's Hospital, Inc. |
Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
|
AU2018266131B2
(en)
|
2017-05-08 |
2021-07-29 |
Alivio Therapeutics, Inc. |
Formulation of nanostructured gels for increased agent loading and adhesion
|
TW201900160A
(zh)
|
2017-05-19 |
2019-01-01 |
愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 |
用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
FI4056176T3
(fi)
|
2018-09-24 |
2024-05-30 |
Amarin Pharmaceuticals Ie Ltd |
Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa
|
MX2022011743A
(es)
|
2020-03-26 |
2022-12-08 |
Plx Opco Inc |
Portadores farmaceuticos con capacidad de reconstitucion dependiente del ph y metodos para elaborar y usar los mismos.
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|